1. Home
  2. MEIP

MEIP

MEI Pharma Inc.

Logo MEI Pharma Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-19-2024 4:00pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.

Founded: 2000 Country:
United States
United States
Employees: 46 City: SAN DIEGO
Market Cap: 21.7M IPO Year: 2003
Target Price: $43.50 AVG Volume (30 days): 22.2K
Analyst Decision: Buy Number of Analysts: 2
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: 2.97 EPS Growth: N/A
52 Week Low/High: $3.21 - $7.97 Next Earning Date: 05-09-2024
Revenue: $72,648,000 Revenue Growth: 16.10%
Revenue Growth (this year): 36.62% Revenue Growth (next year): -90.44%

Share on Social Networks: